ITEM#: 3042-9000411G
MFR#: 900041-1G
Iron oxide (II,III), nanopowder 15 nm avg. part. size (TEM), NHS ester functionalized
Product Name | Description | Item# | QTY | |
---|---|---|---|---|
Iron oxide (II,III), nanopowder 25 nm, NHS ester functionalized | Iron oxide (II,III), nanopowder 25 nm, NHS ester functionalized | 3042-9000341G | EA | |
Iron oxide (II,III), nanoparticles 15 nm avg. part. size (TEM), PEG functionalized, 1 mg/mL in H2O | Iron oxide (II,III), nanoparticles 15 nm avg. part. size (TEM), PEG functionalized, 1 mg/mL in H2O | 3042-90002610ML | EA | |
Iron oxide (II,III), nanoparticles 15 nm avg. part. size (TEM), amine functionalized, 1 mg/mL in H2O | Iron oxide (II,III), nanoparticles 15 nm avg. part. size (TEM), amine functionalized, 1 mg/mL in H2O | 3042-90019910ML | EA | |
Iron oxide (II,III), nanoparticles 15 nm avg. part. size (TEM), streptavidin functionalized, 1 mg/mL in H2O | Iron oxide (II,III), nanoparticles 15 nm avg. part. size (TEM), streptavidin functionalized, 1 mg/mL in H2O | 3042-9000921ML | EA | |
Iron oxide (II,III), nanoparticles 15 nm avg. part. size (TEM), carboxylic acid functionalized, 5 mg/mL in H2O | Iron oxide (II,III), nanoparticles 15 nm avg. part. size (TEM), carboxylic acid functionalized, 5 mg/mL in H2O | 3042-9002002ML | EA | |
Iron oxide (II,III), nanoparticles 15 nm avg. part. size (TEM), 5 mg/mL in H2O | Iron oxide (II,III), nanoparticles 15 nm avg. part. size (TEM), 5 mg/mL in H2O | 3042-9000435ML | EA | |
Iron oxide (II,III), nanoparticles 15 nm avg. part. size (TEM), 5 mg/mL in toluene | Iron oxide (II,III), nanoparticles 15 nm avg. part. size (TEM), 5 mg/mL in toluene | 3042-9000635ML | EA | |
Iron oxide (II,III), nanoparticles 10 nm avg. part. size (TEM), streptavidin functionalized, 1 mg/mL in H2O | Iron oxide (II,III), nanoparticles 10 nm avg. part. size (TEM), streptavidin functionalized, 1 mg/mL in H2O | 3042-9000911ML | EA | |
Iron oxide (II,III), nanoparticles 30 nm avg. part. size (TEM), streptavidin functionalized, 1 mg/mL in H2O | Recent docking studies highlight the potential interaction of iron oxide (II,III) nanoparticles (IONPs) with the SARS-CoV-2 spike protein receptor binding domain. This may target viral entry in host cells and also render virions inactive. | 3042-9001481ML | EA |
Thank you for visiting, your account is pending approval.
You will received email notification for approval within 24hrs.
Contact customerservice@franklinyoung.com for any questions.
Thank you for requesting an account with Franklin Young.
Your request has been declined
We restrict website access to government entities, and related customers.
Please contact customerservice@franklinyoung.com with any questions.